Targeting of RecQ Helicases as a Novel Therapeutic Strategy for Ovarian Cancer

被引:6
|
作者
Maity, Jyotirindra [1 ]
Horibata, Sachi [2 ,3 ,4 ]
Zurcher, Grant [1 ]
Lee, Jung-Min [1 ]
机构
[1] NCI, Womens Malignancies Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[2] NCI, Cell Biol Lab, Ctr Canc Res, NIH, Bethesda, MD 20892 USA
[3] Michigan State Univ, Precis Hlth Program, E Lansing, MI 48824 USA
[4] Michigan State Univ, Coll Human Med, Dept Pharmacol & Toxicol, E Lansing, MI 48824 USA
基金
美国国家卫生研究院;
关键词
ovarian cancer; RecQ helicases; BLM; WRN; RECQL4; novel treatment; WERNER-SYNDROME PROTEIN; ROTHMUND-THOMSON-SYNDROME; SYNDROME GENE-PRODUCT; BLOOMS-SYNDROME; DNA-DAMAGE; FUNCTIONAL INTERACTION; ATM ACTIVATION; FANCONI-ANEMIA; BLM HELICASE; EXPRESSION;
D O I
10.3390/cancers14051219
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
RecQ helicases are essential for DNA replication, recombination, DNA damage repair, and other nucleic acid metabolic pathways required for normal cell growth, survival, and genome stability. More recently, RecQ helicases have been shown to be important for replication fork stabilization, one of the major mechanisms of PARP inhibitor resistance. Cancer cells often have upregulated helicases and depend on these enzymes to repair rapid growth-promoted DNA lesions. Several studies are now evaluating the use of RecQ helicases as potential biomarkers of breast and gynecologic cancers. Furthermore, RecQ helicases have attracted interest as possible targets for cancer treatment. In this review, we discuss the characteristics of RecQ helicases and their interacting partners that may be utilized for effective treatment strategies (as cancers depend on helicases for survival). We also discuss how targeting helicase in combination with DNA repair inhibitors (i.e., PARP and ATR inhibitors) can be used as novel approaches for cancer treatment to increase sensitivity to current treatment to prevent rise of treatment resistance.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Targeting mitophagy for depression amelioration: a novel therapeutic strategy
    Xu, Wangjun
    Gao, Weiping
    Guo, Yukun
    Xue, Feng
    Di, Lulu
    Fang, Shaojie
    Fan, Linlin
    He, Yangyang
    Zhou, Yunfeng
    Xie, Xinmei
    Pang, Xiaobin
    FRONTIERS IN NEUROSCIENCE, 2023, 17
  • [22] Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer
    Huang, Tzu-Ting
    Lampert, Erika J.
    Coots, Cynthia
    Lee, Jung-Min
    CANCER TREATMENT REVIEWS, 2020, 86
  • [23] Role of lncRNAs as Novel Biomarkers and Therapeutic Targets in Ovarian Cancer
    Fu, Lu-lu
    Li, Chun-jin
    Xu, Ying
    Li, Ling-yun
    Zhou, Xu
    Li, Dan-dan
    Chen, Shu-xiong
    Wang, Feng-ge
    Zhang, Xue-ying
    Zheng, Lian-wen
    CRITICAL REVIEWS IN EUKARYOTIC GENE EXPRESSION, 2017, 27 (02): : 183 - 195
  • [24] Berberine: A novel therapeutic strategy for cancer
    Samadi, Parisa
    Sarvarian, Parisa
    Gholipour, Elham
    Asenjan, Karim Shams
    Aghebati-Maleki, Leili
    Motavalli, Roza
    Hojjat-Farsangi, Mohammad
    Yousefi, Mehdi
    IUBMB LIFE, 2020, 72 (10) : 2065 - 2079
  • [25] Tumor Microenvironment in Ovarian Cancer: Function and Therapeutic Strategy
    Yang, Yanfei
    Yang, Yang
    Yang, Jing
    Zhao, Xia
    Wei, Xiawei
    FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2020, 8
  • [26] YAP silencing as a new therapeutic strategy for ovarian cancer
    Roh, Ju-Won
    Kim, Jongseung
    Choi, Jeong Eun
    Han, Hee Dong
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2018, 28 : 101 - 102
  • [27] Combinatorial targeting of menin and the histone methyltransferase DOT1L as a novel therapeutic strategy for treatment of chemotherapy-resistant ovarian cancer
    Elena Alexandrova
    Jessica Lamberti
    Domenico Memoli
    Claudia Quercia
    Viola Melone
    Francesca Rizzo
    Roberta Tarallo
    Giorgio Giurato
    Giovanni Nassa
    Alessandro Weisz
    Cancer Cell International, 22
  • [28] Targeting Sphingolipid Metabolism as a Therapeutic Strategy in Cancer Treatment
    Janneh, Alhaji H.
    Ogretmen, Besim
    CANCERS, 2022, 14 (09)
  • [29] Therapeutic targeting of glutaminolysis as an essential strategy to combat cancer
    Mates, Jose M.
    Di Paola, Floriana J.
    Campos-Sandoval, Jose A.
    Mazurek, Sybille
    Marquez, Javier
    SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2020, 98 : 34 - 43
  • [30] The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer
    Q Sheng
    J Liu
    British Journal of Cancer, 2011, 104 : 1241 - 1245